Navigation Links
Regeneron Announces Panel Discussion at Citi's 5th Annual Biotech Day
Date:9/28/2010

TARRYTOWN, N.Y., Sept. 28 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) will participate in a webcast panel discussion on the topic "Eye Diseases: Novel Therapies for Wet AMD, Retinal Vein Occlusion and Diabetic Macular Edema" at Citi's 5th Annual Biotech Day on Tuesday, October 5, 2010.  The panel discussion will be broadcast live at 8:00 a.m. Eastern Time and may be accessed through the Company's web site, www.regeneron.com, on the Investor Relations page.  An archived version of the presentation will be available after the live webcast through November 4, 2010.  

Regeneron is a fully integrated biopharmaceutical company that discovers, develops, and commercializes medicines for the treatment of serious medical conditions.  In addition to ARCALYST® (rilonacept) Injection for Subcutaneous Use, its first commercialized product, Regeneron has therapeutic candidates in Phase 3 clinical trials for the potential treatment of gout, diseases of the eye (wet age-related macular degeneration and central retinal vein occlusion), and certain cancers.  Additional therapeutic candidates developed from proprietary Regeneron technologies for creating fully human monoclonal antibodies are in earlier stage development programs in rheumatoid arthritis and other inflammatory conditions, pain, cholesterol reduction, allergic and immune conditions and cancer.  Additional information about Regeneron and recent news releases are available on Regeneron's web site at www.regeneron.com. Contact Information:Michael Aberman, M.D.Investor Relations914.345.7799michael.aberman@regeneron.comPeter DworkinCorporate Communications914.345.7800peter.dworkin@regeneron.com
'/>"/>

SOURCE Regeneron Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Bayer and Regeneron Dose First Patient in Second Phase 3 Study for VEGF Trap-Eye in Wet Age-Related Macular Degeneration
2. Bayer and Regeneron Extend Development Program for VEGF Trap-Eye to Include Central Retinal Vein Occlusion
3. Enrollment Completed in Regeneron and Bayer HealthCare Phase 3 Studies of VEGF Trap-Eye in Neovascular Age-Related Macular Degeneration (Wet AMD)
4. Regeneron Announces Presentation at the 18th Annual Credit Suisse Healthcare Conference
5. Regeneron Reports Third Quarter 2009 Financial and Operating Results
6. Sanofi-aventis and Regeneron Expand Strategic Antibody Collaboration
7. Regeneron Announces Presentation at the Deutsche Bank 2009 Biotech Boston Confab
8. BioMed Realty Trust Signs New Lease With Regeneron Pharmaceuticals for 131,000 Square Feet at Landmark
9. Regeneron Announces Presentation at the Morgan Stanley Global Healthcare Conference
10. Regeneron Announces Presentation at the UBS Global Life Sciences Conference
11. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... 2, 2014   Intrexon Corporation (NYSE: ... announced that it has entered into an Exclusive Channel ... of Sanofi (EURONEXT: SAN and NYSE: SNY ... specific family of its marketed Active Pharmaceutical Ingredients (APIs) ... . This collaboration will leverage Intrexon,s proprietary technology ...
(Date:9/2/2014)... Calif. , Sept. 2, 2014 Cepheid ... Flu/RSV XC, an on-demand molecular test for ... Flu B, and differentiation of RSV infection. The ... under the European Directive on In Vitro ... of tests available to eighteen. Xpert Flu/RSV XC runs ...
(Date:9/2/2014)... -- Sinovac Biotech Ltd. (NASDAQ: SVA ), a leading ... today announced that the Company,s management will participate in the ... Global Healthcare Conference, to be held at the Grand Hyatt ... Morgan Stanley Asia Pacific Healthcare Day, to be held at ... Aegis Healthcare & Technology Conference, to be held at the ...
Breaking Medicine Technology:Intrexon Announces Exclusive Channel Collaboration with Sanofi to Optimize Production for a Specific Family of Active Pharmaceutical Ingredients 2Intrexon Announces Exclusive Channel Collaboration with Sanofi to Optimize Production for a Specific Family of Active Pharmaceutical Ingredients 3Cepheid Announces European Release of Xpert Flu/RSV XC for Accurate and Reliable Detection and Differentiation of Flu A, Flu B, and RSV Infection 2Cepheid Announces European Release of Xpert Flu/RSV XC for Accurate and Reliable Detection and Differentiation of Flu A, Flu B, and RSV Infection 3Cepheid Announces European Release of Xpert Flu/RSV XC for Accurate and Reliable Detection and Differentiation of Flu A, Flu B, and RSV Infection 4Sinovac to Participate in Upcoming Investor Conferences 2
... VirtualScopics, Inc. (Nasdaq: VSCP ), a leading provider of ... balance (the amount remaining to be recognized from its active ... the clinical research industry), exceeds $35 million which compares to ... greater than 90% increase. The average duration of the studies ...
... Sparta Systems, Inc., the maker of TrackWise® software ... compliance solutions, today announced that Ascent Healthcare Solutions, ... has selected its TrackWise Enterprise Quality Management System ... compliance with industry regulations. Ascent will deploy ...
Cached Medicine Technology:VirtualScopics' Project Balance Exceeds a Record $35 Million 2VirtualScopics' Project Balance Exceeds a Record $35 Million 3Leading Medical Device Provider Chooses TrackWise(R) Software to Optimize Customer Complaint Handling 2Leading Medical Device Provider Chooses TrackWise(R) Software to Optimize Customer Complaint Handling 3
(Date:9/2/2014)... 2014 West Hollywood cosmetic dentist ... for Invisalign. This special offer includes a free consultation ... determine their candidacy for the procedure and answer any ... may also be eligible for the Summer Invisalign special, ... the month of August, patients who choose Invisalign will ...
(Date:9/2/2014)... Dennis Thompson HealthDay Reporter ... early or at low birth weight are at risk later ... problems that increase their risk for heart disease, according to ... children face potential lifetime disadvantages, researchers in both studies ... found that these obstacles can be overcome. Education appeared ...
(Date:9/2/2014)... 02, 2014 Moroccan Eco-Biologics’ new one-of-a-kind ... formulated, while preserving the foundation of all natural Moroccan ... and scalp problems. There is nothing similar to Vitality ... , Hair loss is a commonly encountered problem for ... for treatment have been limited to existing medications offering ...
(Date:9/2/2014)... 02, 2014 USARAD Holdings Inc. ... telemedicine solutions provider, including SecondOpinions.com® – consumer division ... technologically advanced services. The telemedicine industry pioneer is ... Kuwait. , Founded and established in 1963 as ... Shifa began as a maternity care hospital with ...
(Date:9/2/2014)... 02, 2014 The global market for ... million by 2020, growing at an estimated CAGR of ... study by Grand View Research, Inc. Peripheral vascular devices ... devices are used for treating peripheral arterial or coronary ... plaques in arteries. These devices are used to decrease ...
Breaking Medicine News(10 mins):Health News:West Hollywood Cosmetic Dentist, Dr. Poneh Ghasri, Now Offers Complimentary Consultations for Invisalign 2Health News:Preterm or Small Birth Tied to Long-Term Risks to Heart, Brain 2Health News:Preterm or Small Birth Tied to Long-Term Risks to Heart, Brain 3Health News:New All Natural, Organic Hair Recovery Products by Moroccan Eco-Biologics, Restore Lost Hair with No Side Effects 2Health News:USARAD Holdings Inc. SECONDOPINIONS.COM® Partners With Prestigious Dar Al Shifa Hospital In Kuwait 2Health News:USARAD Holdings Inc. SECONDOPINIONS.COM® Partners With Prestigious Dar Al Shifa Hospital In Kuwait 3Health News:USARAD Holdings Inc. SECONDOPINIONS.COM® Partners With Prestigious Dar Al Shifa Hospital In Kuwait 4Health News:Peripheral Vascular Devices Market By Product (Peripheral Vascular Stents, PTA Guidewires, Atherectomy Devices) Is Expected To Reach USD 8,918.8 Million By 2020 2Health News:Peripheral Vascular Devices Market By Product (Peripheral Vascular Stents, PTA Guidewires, Atherectomy Devices) Is Expected To Reach USD 8,918.8 Million By 2020 3Health News:Peripheral Vascular Devices Market By Product (Peripheral Vascular Stents, PTA Guidewires, Atherectomy Devices) Is Expected To Reach USD 8,918.8 Million By 2020 4Health News:Peripheral Vascular Devices Market By Product (Peripheral Vascular Stents, PTA Guidewires, Atherectomy Devices) Is Expected To Reach USD 8,918.8 Million By 2020 5
... who wear bifocal lenses to help them focus accurately may ... new research from Cardiff University. , The Cardiff School of ... the reasons for poor focussing among children with Downs syndrome. ... study who adopted bifocals to ease difficulties in focusing on ...
... April 29 BioElectronics,Corporation, (Pink Sheets: BIEL), announced ... the ActiPatch products to the Italian market. TSS ... both pharmacies,and consumers in Italy. TSS Medical is ... and is headquartered in Torino, Italy. Over,10,000 ActiPatch ...
... ... Characteristics of New Drugs, BOSTON, April 29 ... provider of commercial open-source "R",software for computational statistics, today released ... Quad-Core AMD,Systems," a study conducted in partnership with Pfizer on ...
... get them at the wrong time, CDC study finds , , ... more than a quarter of American toddlers may be under-vaccinated. ... months found that missed doses account for about two-thirds of ... issue, according to a study conducted by the U.S. Centers ...
... HCA announces the,following Webcast:, What: ... 9:00am CT, Where: http://www.videonewswire.com/event.asp?id=47214 , How: ... on to the web at the ... to participate during the live webcast, the call will,be archived on the ...
... management expertise to executive role, SEATTLE, April ... the appointment of John Havard as the company,s ... 21 years experience,to the Stratos team of product ... as some of the best talent,in complex technology ...
Cached Medicine News:Health News:A life 'lens' ordinary 2Health News:BioElectronics Corporation Announces New Website for Italian Market 2Health News:BioElectronics Corporation Announces New Website for Italian Market 3Health News:Pfizer Partners with REvolution Computing to Improve Medicine Production Pipeline 2Health News:Pfizer Partners with REvolution Computing to Improve Medicine Production Pipeline 3Health News:1 in 4 U.S. Toddlers Improperly Vaccinated 2Health News:1 in 4 U.S. Toddlers Improperly Vaccinated 3Health News:Stratos Product Development Welcomes Back John Havard as Vice President of Engineering 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: